Revelation Biosciences issues stockholder rights dividend under new poison pill plan

Revelation Biosciences

Revelation Biosciences

REVB

0.00
  • Revelation Biosciences adopted a stockholder rights plan, issuing one right per common share via a dividend.
  • Rights payable to holders of record on July 21, 2026.
  • Rights become exercisable if an investor group crosses 10% ownership, or 15% for certain passive institutional investors.
  • Each right allows purchase of 1/1,000 of Series B Junior Participating Preferred Stock at an exercise price of $20.
  • Rights expire July 10, 2027 unless stockholders approve, extending the term to three years from approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607101605ACCESSWRNAPR_____1189185) on July 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.